Alembic Pharmaceuticals Receives USFDA Final Approval for Haloperidol Tablets

Product: Haloperidol Tablets (1 mg, 2 mg, 5 mg, 10 mg, and 20 mg)
Market Size (12 months ending March 2026): US$ 27 million

Reader Takeaway: USFDA approval for a new drug offers revenue potential; pipeline growth shows consistent execution.

What just happened

Alembic Pharmaceuticals Ltd. has received final approval from the U.S. Food and Drug Administration (USFDA) for its Haloperidol Tablets. These tablets are available in strengths of 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg. The approved product is therapeutically equivalent to the reference drug, Haldol Tablets, originally manufactured by Ortho McNeil.

Why this matters

This approval allows Alembic Pharmaceuticals to market Haloperidol Tablets in the United States. The drug is indicated for managing psychotic disorders and controlling tics and vocal utterances in patients with Tourette’s Disorder. According to IQVIA data, the estimated market size for this specific product is US$27 million for the twelve months ending March 2026. This approval contributes to the company's ongoing strategy to expand its presence in the lucrative U.S. generic drug market.

The backstory

Alembic Pharmaceuticals has a consistent track record of securing USFDA approvals. This latest approval brings the company's cumulative total of Abbreviated New Drug Application (ANDA) approvals to 240. This total comprises 221 final approvals and 19 tentative approvals, reflecting sustained research and development efforts and successful regulatory navigation.

What changes now

With this final approval, Alembic Pharmaceuticals can now proceed with the commercial launch of Haloperidol Tablets in the U.S. market. Investors will be keen to observe the product's performance in upcoming financial quarters and its contribution to the company's overall revenue from the U.S. generics segment.

Risks to watch

While the approval is positive, the actual revenue generated will depend on market acceptance, competition, and pricing strategies. The modest market size for this single product means its impact on overall financials might be limited, though it adds to the breadth of the company's portfolio.

Peer comparison

Many pharmaceutical companies, including those listed in India, actively seek USFDA approvals for generic drugs. Companies like Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and Cipla also have significant portfolios of approved ANDAs and a strong presence in the U.S. market. Alembic's consistent approval rate places it among these active players.

Context metrics (time-bound)

• Market Size: US$ 27 million (12 months ending March 2026)
• Cumulative Final ANDA Approvals: 221 (as of June 5, 2026)
• Cumulative Tentative ANDA Approvals: 19 (as of June 5, 2026)
• Total Cumulative ANDA Approvals: 240 (as of June 5, 2026)

What to track next

Investors should monitor Alembic Pharmaceuticals' quarterly results for specific sales figures related to Haloperidol Tablets and any new ANDA approvals announced. The company's ability to successfully launch and market this product will be a key indicator of its execution capabilities.